Access to stem cell transplantation: Do women fare as well as men?

Paulette Mehta, Bradley H Pollock, Melodee Nugent, Mary Horowitz, John R. Wingard

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Women have less access to certain types of expensive treatments including renal transplantation, cardiac catheterization and diagnostic studies for lung cancer. Whether women have less access to stem cell transplantation (SCT) is not known. We evaluated allogeneic SCT data from the International Bone Marrow Transplant Registry (IBMTR) and compared them with disease incidence data from the Surveillance and Epidemiologic End Results (SEER) database. We estimated the ratio of males to females among transplanted patients with acute lymphoblastic (ALL), acute myelogenous (AML) and chronic myelogenous (CML) leukemia, diseases for which SCT is often done and compared them to male/female ratios of disease incidence. The association between gender and SCT was estimated as odds ratios (OR) with 95% confidence intervals (Cl). There was no association between gender (male vs female) and the rates of SCT for individuals with AML (OR = 0.95, 95% Cl = 0.89-1.02), or CML (OR = 1.0; Cl = 0.90-1.1). Among patients with newly diagnosed ALL, more males underwent SCT than females (OR = 1.30, Cl = 1.18-1.44). Because children with newly diagnosed ALL usually have a favorable prognosis, SCT is not generally a frontline therapy. Therefore, when we compared SCT rates to a population of children with relapsed ALL, the gender differences disappeared (OR = 1.09, Cl = 0.94-1.25). We conclude that for the diagnoses where SCT is commonly used, there is no significant bias towards use in males compared to females. While boys with ALL appear to receive SCT at a higher rate, this difference is likely attributable to biological rather than social reasons.

Original languageEnglish (US)
Pages (from-to)99-102
Number of pages4
JournalAmerican Journal of Hematology
Volume72
Issue number2
DOIs
StatePublished - Feb 1 2003
Externally publishedYes

Fingerprint

Stem Cell Transplantation
Odds Ratio
Epidemiological Monitoring
Incidence
Cardiac Catheterization
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Kidney Transplantation
Registries
Lung Neoplasms
Bone Marrow
Databases
Confidence Intervals
Transplants

Keywords

  • Access
  • Gender bias
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Access to stem cell transplantation : Do women fare as well as men? / Mehta, Paulette; Pollock, Bradley H; Nugent, Melodee; Horowitz, Mary; Wingard, John R.

In: American Journal of Hematology, Vol. 72, No. 2, 01.02.2003, p. 99-102.

Research output: Contribution to journalArticle

Mehta, Paulette ; Pollock, Bradley H ; Nugent, Melodee ; Horowitz, Mary ; Wingard, John R. / Access to stem cell transplantation : Do women fare as well as men?. In: American Journal of Hematology. 2003 ; Vol. 72, No. 2. pp. 99-102.
@article{5bdae3fce81a461d9895a8e4a47a60b4,
title = "Access to stem cell transplantation: Do women fare as well as men?",
abstract = "Women have less access to certain types of expensive treatments including renal transplantation, cardiac catheterization and diagnostic studies for lung cancer. Whether women have less access to stem cell transplantation (SCT) is not known. We evaluated allogeneic SCT data from the International Bone Marrow Transplant Registry (IBMTR) and compared them with disease incidence data from the Surveillance and Epidemiologic End Results (SEER) database. We estimated the ratio of males to females among transplanted patients with acute lymphoblastic (ALL), acute myelogenous (AML) and chronic myelogenous (CML) leukemia, diseases for which SCT is often done and compared them to male/female ratios of disease incidence. The association between gender and SCT was estimated as odds ratios (OR) with 95{\%} confidence intervals (Cl). There was no association between gender (male vs female) and the rates of SCT for individuals with AML (OR = 0.95, 95{\%} Cl = 0.89-1.02), or CML (OR = 1.0; Cl = 0.90-1.1). Among patients with newly diagnosed ALL, more males underwent SCT than females (OR = 1.30, Cl = 1.18-1.44). Because children with newly diagnosed ALL usually have a favorable prognosis, SCT is not generally a frontline therapy. Therefore, when we compared SCT rates to a population of children with relapsed ALL, the gender differences disappeared (OR = 1.09, Cl = 0.94-1.25). We conclude that for the diagnoses where SCT is commonly used, there is no significant bias towards use in males compared to females. While boys with ALL appear to receive SCT at a higher rate, this difference is likely attributable to biological rather than social reasons.",
keywords = "Access, Gender bias, Stem cell transplantation",
author = "Paulette Mehta and Pollock, {Bradley H} and Melodee Nugent and Mary Horowitz and Wingard, {John R.}",
year = "2003",
month = "2",
day = "1",
doi = "10.1002/ajh.10273",
language = "English (US)",
volume = "72",
pages = "99--102",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Access to stem cell transplantation

T2 - Do women fare as well as men?

AU - Mehta, Paulette

AU - Pollock, Bradley H

AU - Nugent, Melodee

AU - Horowitz, Mary

AU - Wingard, John R.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Women have less access to certain types of expensive treatments including renal transplantation, cardiac catheterization and diagnostic studies for lung cancer. Whether women have less access to stem cell transplantation (SCT) is not known. We evaluated allogeneic SCT data from the International Bone Marrow Transplant Registry (IBMTR) and compared them with disease incidence data from the Surveillance and Epidemiologic End Results (SEER) database. We estimated the ratio of males to females among transplanted patients with acute lymphoblastic (ALL), acute myelogenous (AML) and chronic myelogenous (CML) leukemia, diseases for which SCT is often done and compared them to male/female ratios of disease incidence. The association between gender and SCT was estimated as odds ratios (OR) with 95% confidence intervals (Cl). There was no association between gender (male vs female) and the rates of SCT for individuals with AML (OR = 0.95, 95% Cl = 0.89-1.02), or CML (OR = 1.0; Cl = 0.90-1.1). Among patients with newly diagnosed ALL, more males underwent SCT than females (OR = 1.30, Cl = 1.18-1.44). Because children with newly diagnosed ALL usually have a favorable prognosis, SCT is not generally a frontline therapy. Therefore, when we compared SCT rates to a population of children with relapsed ALL, the gender differences disappeared (OR = 1.09, Cl = 0.94-1.25). We conclude that for the diagnoses where SCT is commonly used, there is no significant bias towards use in males compared to females. While boys with ALL appear to receive SCT at a higher rate, this difference is likely attributable to biological rather than social reasons.

AB - Women have less access to certain types of expensive treatments including renal transplantation, cardiac catheterization and diagnostic studies for lung cancer. Whether women have less access to stem cell transplantation (SCT) is not known. We evaluated allogeneic SCT data from the International Bone Marrow Transplant Registry (IBMTR) and compared them with disease incidence data from the Surveillance and Epidemiologic End Results (SEER) database. We estimated the ratio of males to females among transplanted patients with acute lymphoblastic (ALL), acute myelogenous (AML) and chronic myelogenous (CML) leukemia, diseases for which SCT is often done and compared them to male/female ratios of disease incidence. The association between gender and SCT was estimated as odds ratios (OR) with 95% confidence intervals (Cl). There was no association between gender (male vs female) and the rates of SCT for individuals with AML (OR = 0.95, 95% Cl = 0.89-1.02), or CML (OR = 1.0; Cl = 0.90-1.1). Among patients with newly diagnosed ALL, more males underwent SCT than females (OR = 1.30, Cl = 1.18-1.44). Because children with newly diagnosed ALL usually have a favorable prognosis, SCT is not generally a frontline therapy. Therefore, when we compared SCT rates to a population of children with relapsed ALL, the gender differences disappeared (OR = 1.09, Cl = 0.94-1.25). We conclude that for the diagnoses where SCT is commonly used, there is no significant bias towards use in males compared to females. While boys with ALL appear to receive SCT at a higher rate, this difference is likely attributable to biological rather than social reasons.

KW - Access

KW - Gender bias

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=12244268630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244268630&partnerID=8YFLogxK

U2 - 10.1002/ajh.10273

DO - 10.1002/ajh.10273

M3 - Article

C2 - 12555212

AN - SCOPUS:12244268630

VL - 72

SP - 99

EP - 102

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -